Guardion Health Sciences To Delist as It Goes Into Liquidation; Appoints Interim CEO, President

Dow Jones10-01
 

By Michael Susin

 

Guardion Health Sciences on Tuesday requested the Nasdaq Stock Market to delist its stock as part of its liquidation and dissolution plans.

The clinical nutrition company said it expects to suspend trading of its stock prior to the opening of trading on Oct. 14, and for the official delisting to be effective Oct. 21.

The company also announced that it has appointed Mark Goldstone as interim president and interim chief executive, effective Oct. 18, replacing Jan Hall.

The liquidation plan was authorized by its shareholders on May 31. The dissolution follows the completion of the sale of the Viactiv brand and business, which left the company with minimal operations.

 

Write to Michael Susin at michael.susin@wsj.com

 

(END) Dow Jones Newswires

October 01, 2024 09:24 ET (13:24 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment